Increased bioavailability of 11-keto-β-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: Modeling and simulation considerations for evaluating drug exposures

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1592-1600

  Skarke, Carsten ^a,b   Kuczka, Karina ^b   Tausch, Lars ^b   Werz, Oliver ^c   Rossmanith, Tanja ^b   Barrett, Jeffrey S ^d   Harder, Sebastian ^b   Holtmeier, Wolfgang ^e   Schwarz, Joachim A ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Children's Hospital of Philadelphia ^*

Author keywords

Boswelan; boswellic acid; dose projections; frankincense; healthy volunteers; pharmacokinetics

Indexed keywords

11 OXO BETA BOSWELLIC ACID; 3 ACETYL 11 KETO BETA BOSWELLIC ACID; BOSWELLIA SERRATA EXTRACT; CATHEPSIN G; DRUG METABOLITE; PLACEBO; TERPENOID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOSWELLIA; BOSWELLIA SERRATA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG ISOLATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BOSWELLIA; CATHEPSIN G; COMPUTER SIMULATION; CROSS-OVER STUDIES; EICOSANOIDS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MEALS; MODELS, BIOLOGICAL; PLANT EXTRACTS; PLATELET AGGREGATION; TRITERPENES;

EID: 84868037032     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011422811     Document Type: Article

References (43)

1. Safayhi H, Ammon H.. Pharmakologische Aspekte von Weihrauch und Boswelliasaeren. Pharmazeutische Zeitung. 1997 ; 142: 11-20
2. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP.. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992 ; 261: 1143-1146
3. Sailer E-R, Hoernlein RF, Ammon HPT, Safayhi H.. Structure-activity relationships of the nonredox-type non-competitive leukotriene biosynthesis inhibitor acetyl-11-keto-b-boswellic acid. Phytomedicine. 1996 ; 4: 73-74
4. Poeckel D, Werz O.. Boswellic acids: biological actions and molecular targets. Curr Med Chem. 2006 ; 13: 3359-3369
5. Boswellia serrata - monograph. Altern Med Rev. 2008 ; 13: 165-168
6. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998 ; 3: 511-514
7. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997 ; 2: 37-43
8. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B.. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991 ; 33: 91-95
9. Chopra A, Lavin P, Patwardhan B, Chitre D.. Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol. 2000 ; 27: 1365-1372
10. Basch E, Boon H, Davies-Heerema T, et al. Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother. 2004 ; 4: 63-83
11. Mursch K, Behnke-Mursch J.. Internet-based interaction among brain tumour patients: analysis of a medical mailing list. Zentralbl Neurochir. 2003 ; 64: 71-75
12. Paul M, Puteanus U, Stapel U Import von Arzneimitteln- Nutzen und Risiken fur die Bevolkerung. Eine sozialpharmazeutische Untersuchung der Amtsapothekerinnen und Amtsapotheker in Nordrhein-Westfalen. Münster, Germany: Institute of Public Health North Rhine-Westphalia ; 2005 :
13. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B.. Use of complementary and alternative medicine in Germany: a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006 ; 6: 19
14. Sterk V, Buchele B, Simmet T.. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. 2004 ; 70: 1155-1160
15. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G.. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997 ; 22: 39-52
16. Kaunzinger A, Baumeister A, Cuda K, et al. Determination of 11-keto-boswellic acid in human plasma. J Pharm Biomed Anal. 2002 ; 28: 729-739
17. Reising K, Meins J, Bastian B, et al. Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem. 2005 ; 77: 6640-6645
18. Jauch J, Bergmann J.. An efficient method for the large-scale preparation of 3-O-acetyl-11-oxo-β-boswellic acid and other boswellic acids. Eur J Org Chem. 2003 ; 24: 4752-4756
19. Siemoneit U, Pergola C, Jazzar B, et al. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol. 2009 ; 606: 246-254
20. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 ; 17: 317-327
21. Patrignani P, Filabozzi P, Patrono C.. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 ; 69: 1366-1372
22. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C.. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997 ; 48: 623-631
23. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994 ; 271: 1705-1712
24. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost. 2007 ; 5: 2376-2385
25. Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S.. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther. 2002 ; 40: 135-141
26. Tausch L, Henkel A, Siemoneit U, et al. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol. 2009 ; 183: 3433-3442
27. Suissa S, Shuster JJ.. The 2 × 2 matched-pairs trial: exact unconditional design and analysis. Biometrics. 1991 ; 47: 361-372
28. Newcombe RG.. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998 ; 17: 2635-2650
29. Holtmeier W, Zeuzem S, Preibeta J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. 2011 ; 17: 573-582
30. Doyle MJ, Eichhold TH, Hynd BA, Weisman SM.. Determination of leukotriene B4 in human plasma by gas chromatography using a mass selective detector and a stable isotope labelled internal standard: effect of NE-11740 on arachidonic acid metabolism. J Pharm Biomed Anal. 1990 ; 8: 137-142
31. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004 ; 109: 1468-1471
32. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.. Pharmacokinetic study of 11-keto beta-boswellic acid. Phytomedicine. 2004 ; 11: 255-260
33. Kruger P, Daneshfar R, Eckert GP, et al. Metabolism of boswellic acids in vitro and in vivo. Drug Metab Dispos. 2008 ; 36: 1135-1142
34. Karlina MV, Pozharitskaya ON, Kosman VM, Ivanova SA.. Bioavailability of boswellic acids: in vitro/in vivo correlation. Pharm Chem J. 2007 ; 41: 569-572
35. Lee PH, Ayyampalayam SN, Carreira LA, et al. In silico prediction of ionization constants of drugs. Mol Pharm. 2007 ; 4: 498-512
36. Siemoneit U, Hofmann B, Kather N, et al. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol. 2008 ; 75: 503-513
37. Ammon HP, Mack T, Singh GB, Safayhi H.. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of. Boswellia serrata. Planta Med. 1991 ; 57: 203-207
38. Kimmatkar N, Thawani V, Hingorani L, Khiyani R.. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003 ; 10: 3-7
39. Krieglstein CF, Anthoni C, Rijcken EJ, et al. Acetyl-11-keto-beta- boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis. 2001 ; 16: 88-95
40. Safayhi H, Sailer ER, Ammon HP.. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995 ; 47: 1212-1216
41. Werz O, Schneider N, Brungs M, et al. A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6. Naunyn Schmiedebergs Arch Pharmacol. 1997 ; 356: 441-445
42. Hoernlein RF, Orlikowsky T, Zehrer C, et al. Acetyl-11-keto-beta- boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther. 1999 ; 288: 613-619
43. Poeckel D, Tausch L, Kather N, Jauch J, Werz O.. Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacol. 2006 ; 70: 1071-1078